Antisense Therapeutics (ASX:ANP) share price tumbles 8% amid capital raise

The company's shares are set to finish the week lower…

| More on:
A man in a white coat holds a laptop in one hand and his head in the other, it's bad news.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares in Antisense Therapeutics Limited (ASX: ANP) are tumbling today following a heavily oversubscribed placement.

At the time of writing, the Antisense share price is trading at 22 cents, down 8.33%. This means that its shares have now fallen more than 20% in the past week alone.

What's driving Antisense shares lower?

A catalyst for today's fall in Antisense shares is that investors may be concerned about an impending share dilution.

According to its release, Antisense advised that both institutional and sophisticated investors took part in the placement. The firm commitments received will raise $20 million for the company through the issuance of around 83.33 million ordinary shares.

The offer price will be listed at 24 cents apiece and includes one free attaching unlisted option with every 2 shares subscribed. The strike price of the exercisable option will be at a price of 48 cents for each share applied. These options will have an expiry date on the earlier of either 20 December 2024 or 20 business days after the acceleration trigger date.

The board noted that many of the company's shareholders did not have the opportunity to participate in the offer. As such, an entitlement offer has been put forward which will enable eligible shareholders to apply for 1 new share for every 9.4 existing shares owned.

The issue price is also listed at 24 cents per new share whilst also receiving one free unlisted option for every 2 new shares issued. This is expected to raise an additional $16.8 million for the company.

Funds collected from the placement will be allocated towards covering a number of costs for the ATL1102 Phase IIb/III clinical study. The clinical trial will run for 52-weeks and will be assessed for muscle strength among a number of participants.

About the Antisense share price

It's been a wild ride for Antisense shareholders, with the company's shares accelerating by almost 80% year to date. Looking at a longer time frame, the Antisense share price is up around 140% since this time last year.

Based on today's price, Antisense presides a market capitalisation of around $137.87 million, with approximately 574 million shares outstanding.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Capital Raising

a business man in a suit holds his hand over his eyes as he bows his head in a defeated post suggesting regret and remorse.
Consumer Staples & Discretionary Shares

Why is this ASX share crashing 60% on Monday?

Shareholders of this stock may need a stiff drink today.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Materials Shares

Why is this ASX lithium stock crashing 16% today?

Why is this stock having such a poor start to the week?

Read more »

happy investor, celebrating investor, good news, share price rise, up, increase
Capital Raising

Nick Scali share price jumps 14% to record high after raising $46m

Investors have responded very positively to the company's UK expansion plan.

Read more »

a man in a british union jack T shirt hurdles high into the air with london bridge visible in the background.
Mergers & Acquisitions

Nick Scali shares halted amid $60m capital raising and UK expansion news

This furniture retailer has its eyes on the UK furniture market.

Read more »

A man sits in a chair hunched over a laptop and covered head to toe in frozen icicles to represent Envirosuite's trading halt
Capital Raising

DroneShield shares freeze on $75 million for AI and inventory

This defence tech stock is rattling the can for a chunk of cash.

Read more »

A woman sits at her computer with her hand to her mouth and a contemplative smile on her face as she reads about the performance of Allkem shares on her computer
Technology Shares

What's happening with the NextDC share price on Thursday?

NextDC is raising $1.32 billion to accelerate its data centre developments amid the rapid growth of AI.

Read more »

A man sits in a chair hunched over a laptop and covered head to toe in frozen icicles to represent Envirosuite's trading halt
Capital Raising

Up 102% in 2024, here's why this ASX All Ords stock is now frozen

Seize the day. This company is ready to cash in on its renewed image.

Read more »

A man slumps crankily over his morning coffee as it pours with rain outside.
Materials Shares

Why is this ASX 300 battery materials stock crashing 20% today?

Its shares are now down by 67% since this time last year.

Read more »